Kisspeptin Dosage: The Studied Doses and the Circulating Ones
Almost every kisspeptin dosage page online quotes a number like 100 mcg subcutaneously a few times a week, then cites human trial results that came from a completely different route and schedule. That gap is the single most important thing to understand before dosing this peptide, and it is what this guide is built around: what was actually given in the trials, what people actually inject, why the pharmacokinetics make those two very different, plus reconstitution math, the kisspeptin-10 versus kisspeptin-54 distinction, and dosing in women. For the underlying biology and the evidence base, start with our kisspeptin peptide overview.
Kisspeptin Dosage Chart
The evidence column here is the point of the table. Read down it before reading across any row.
| Protocol | Dose | Route | Schedule | Evidence |
|---|---|---|---|---|
| Kisspeptin-10, testosterone study | 4 mcg/kg/hour | Continuous IV infusion | 22.5 hours | Published human study in healthy men |
| Kisspeptin-10, bolus | Low mcg/kg range | IV bolus | Single | Dose-ranging studies; LH pulse decays within about an hour |
| Kisspeptin-54, IVF trigger | nmol/kg range | Single subcutaneous | One dose per cycle | Clinical fertility trials |
| Circulating community protocol | 100–200 mcg | Subcutaneous | 2–3x weekly, 4–6 weeks | None; not a route or schedule that has been tested |
What Dose Was Actually Studied
The result everyone cites comes from healthy men given a continuous intravenous infusion of kisspeptin-10 at 4 micrograms per kilogram per hour for 22.5 hours. Mean LH went from 5.4 to 20.8 IU/L and serum testosterone from 16.6 to 24.0 nmol/L, about a 45 percent rise. In the units US labs report, that is roughly 478 to 691 ng/dL.
Now the method. Continuous IV. Nearly a full day. Dose titrated to body weight. Controlled research setting. For an 80 kg man that works out to about 320 mcg per hour, which is around 7.2 mg over the full infusion. Set that against 100 to 200 mcg injected under the skin twice a week and the difference is not a matter of degree. It is a different exposure entirely, delivered by a different route on a different timescale.
Why Half-Life Breaks the Weekly Protocol
Kisspeptin-10 disappears from plasma within a few minutes. Kisspeptin-54 lasts longer, roughly half an hour. Both are short-lived by any standard, and that is not incidental to the biology. Kisspeptin normally acts as a pulse generator upstream of GnRH, so rapid clearance is the design, not a flaw.
This is exactly why the trials used continuous infusion. A single injection produces a sharp LH rise that decays within about an hour, and the system returns to baseline. Two of those pulses a week means the compound is present for a rounding error of the week and absent for the rest. Whether repeated brief pulses accomplish anything durable is an open question that nobody has answered in humans, and it is the question anyone running the community protocol is implicitly betting on.
Kisspeptin-10 vs Kisspeptin-54 Dosing
Both are fragments of the KISS1 gene product and both act at the same receptor, but they are not interchangeable when you are choosing a number. Kisspeptin-10 is the shorter fragment and is what most research vials contain. Kisspeptin-54 is longer-lived and is the form used in fertility work, where single subcutaneous doses in the nanomole-per-kilogram range served as an oocyte maturation trigger in place of hCG.
Doses expressed in nmol/kg for kisspeptin-54 cannot be lifted onto a kisspeptin-10 vial, because the molecular weights differ and so does the duration of action. If a protocol you are reading does not say which fragment it refers to, it is not a protocol worth following. Check the certificate of analysis on the vial for the actual peptide identity before doing any arithmetic; our research peptides guide covers what those documents should show.
Reconstitution and Dose Math
Kisspeptin-10 typically ships as a 5 mg lyophilized vial. Adding 2.5 mL of bacteriostatic water gives 2 mg/mL, at which 0.05 mL on a U-100 insulin syringe (5 units) is 100 mcg and 0.1 mL is 200 mcg. Adding 5 mL instead gives 1 mg/mL, where 0.1 mL is 100 mcg, which is the easier conversion to hold in your head at 6 am.
Introduce the diluent slowly down the vial wall, swirl rather than shake, and refrigerate after reconstitution. Storage rules are in our peptide storage guide, diluent selection in bacteriostatic water, and injection technique in how to inject peptides.
Dosing in Women Is Not the Same Problem
The LH response to kisspeptin-10 is sexually dimorphic in humans. Men respond robustly across the doses tested. Women show a response that varies sharply with menstrual cycle phase, weakest in the follicular phase and much stronger approaching ovulation.
The practical consequence is that a single recommended dose for women is close to meaningless. The same amount given at two points in a cycle produces two different hormonal outcomes. Anything targeting fertility belongs in a clinical setting with monitoring rather than a self-administered protocol; our peptides for fertility guide covers that landscape.
Timing and Cycling
The standard advice is morning dosing on an empty stomach, aligned with the natural LH rhythm, and four to six week runs with a break. Both of these are reasoning by analogy rather than findings. No human study has established a time of day for subcutaneous kisspeptin or a cycle length, because the repeated subcutaneous schedule itself has not been studied.
If you want a defensible structure, use the break for measurement rather than for receptor recovery. Baseline LH and total testosterone before starting, repeat at the end of the run, and compare. That is the only way to find out whether the protocol is doing anything, and it converts an untested schedule into at least a personal experiment with a readout. Our testosterone blood test guide covers which markers to pull.
Safety at These Doses
Imperial College trials involving more than 500 men and women reported kisspeptin as well tolerated with no serious drug-related adverse events at the doses studied. Taken at face value that is a good safety signal, and it is better than most research peptides can claim. The qualifier is exposure duration: those were single infusions or courses measured in hours to days, not months of repeated dosing.
Because kisspeptin sits upstream of the whole reproductive axis, the plausible concerns are systemic rather than local: disrupted menstrual cycling in women, and unpredictable gonadotrophin responses in anyone with an existing endocrine condition or on hormone therapy. Those are mechanistic concerns, not documented harms. Broader signals to watch for are in peptide side effects.
Compared With Enclomiphene and hCG
If the goal is raising LH and testosterone, kisspeptin is the least documented of the obvious options. Enclomiphene blocks estrogen negative feedback at the hypothalamus and has real dose-ranging data behind it. hCG acts directly at the LH receptor, with decades of clinical use and dosing measured in well-characterized units.
Kisspeptin acts one level further upstream, which is the mechanistically elegant position and, on current evidence, the least practically useful one. That trade is worth making only if you accept you are running an experiment. For context on the diagnosis side, see low testosterone symptoms.
Bottom Line
Every impressive kisspeptin result you have read came from a continuous intravenous infusion running most of a day. The dose people actually inject is a fraction of that, by a different route, on a schedule that leaves the peptide absent from circulation for essentially the entire week. That may still do something. Nobody has shown that it does. If you use it, know which fragment is in the vial, keep the arithmetic simple with a 1 mg/mL dilution, and measure LH and testosterone at both ends of the run, because without that you have no way to tell the protocol from placebo.
Frequently Asked Questions About Kisspeptin
There is no standard dose in the sense of an approved label, and the honest answer has two halves. The doses studied in humans were mostly intravenous infusions in a research setting, typically kisspeptin-10 at around 4 micrograms per kilogram per hour. The dose circulating in peptide communities is something else entirely: roughly 100 to 200 mcg subcutaneously, two or three times a week. Those two things are not versions of the same protocol, and the outcomes reported for the first do not transfer to the second.
Kisspeptin-10 clears from plasma in a few minutes. Kisspeptin-54 lasts longer, on the order of half an hour. Both are short. The human studies that produced sustained increases in LH and testosterone did so with continuous infusion running for many hours, precisely because a single injection produces a pulse that is gone almost immediately. A subcutaneous shot twice a week gives you two brief pulses per week against a background of nothing, which is a fundamentally different exposure pattern from what was tested.
In the most-cited work, healthy men received a continuous intravenous infusion of kisspeptin-10 at 4 mcg/kg/hour for 22.5 hours. Mean LH rose from 5.4 to 20.8 IU/L and serum testosterone from 16.6 to 24.0 nmol/L, roughly a 45 percent increase. Read the method alongside the result: that was almost a full day of continuous IV dosing titrated to body weight in a controlled setting, not a subcutaneous injection.
They are different fragments of the same parent peptide with different pharmacokinetics, so the numbers do not carry across. Kisspeptin-10 is the shorter fragment, cleared in minutes, and is what most research-grade vials contain. Kisspeptin-54 lasts longer and is the form used in fertility work, where single subcutaneous doses in the nanomole-per-kilogram range were given as an oocyte maturation trigger. Applying a kisspeptin-54 trigger dose to kisspeptin-10 material is a mistake in both directions.
A 5 mg vial with 2.5 mL of bacteriostatic water gives 2 mg/mL, at which 0.05 mL on a U-100 insulin syringe is 100 mcg. The same vial with 5 mL gives 1 mg/mL, where 0.1 mL is 100 mcg and the mental arithmetic is simpler. Add the water slowly against the vial wall, swirl rather than shake, and refrigerate.
No, and this is one of the better-documented findings. The LH response to kisspeptin-10 is sexually dimorphic. Men respond robustly across doses. In women the response depends heavily on where they are in the menstrual cycle, with the follicular phase producing much weaker responses than the preovulatory window. The same dose at a different cycle point produces a different hormonal result, which makes any single recommended figure for women misleading.
For the protocols in circulation, morning administration on an empty stomach is the usual advice, on the theory of aligning with the natural LH rhythm. Be clear about what that is: reasoning by analogy, not a tested schedule. Nothing in the published human work establishes an optimal time of day for subcutaneous kisspeptin, because subcutaneous kisspeptin on a repeating schedule is not what was studied.
Across trials at Imperial College involving more than 500 men and women, kisspeptin has been reported as well tolerated with no serious drug-related adverse events at the doses studied. That is genuinely reassuring for those exposures, which were single infusions or courses measured in hours to days. There is no published long-term human safety data, and because kisspeptin sits upstream of the entire reproductive axis, effects on menstrual cycling and unpredictable gonadotrophin responses in people with existing endocrine conditions are plausible concerns rather than documented ones.
Community protocols usually run four to six weeks and then stop, on the reasoning that any pathway driven this hard eventually adapts. There is no human data establishing either the need for cycling or the right length of a break. If you want a defensible reason to stop periodically, it is not receptor theory: it is that you should be measuring LH and testosterone against a baseline to find out whether anything is happening at all.
Both alternatives have far more established dosing. Enclomiphene blocks estrogen feedback at the hypothalamus and has dose-ranging human data behind it. hCG acts directly at the LH receptor with decades of clinical use and well-characterized units. Kisspeptin acts further upstream, which is mechanistically elegant, but for anyone whose goal is raising LH and testosterone with a known dose, it is the least documented of the three options.